PLoS One by Carballo-Di\uc3\ua9guez, Alex et al.
RESEARCH ARTICLE
High levels of adherence to a rectal
microbicide gel and to oral Pre-Exposure
Prophylaxis (PrEP) achieved in MTN-017
among men who have sex with men (MSM)
and transgender women
Alex Carballo-Die´guez1*, Ivan C. Bala´n1☯, William Brown, III1,2☯, Rebecca Giguere1☯,
Curtis Dolezal1☯, Cheng-Shiun Leu1☯, Mark A. Marzinke3‡, Craig W. Hendrix3‡, Jeanna
M. Piper4‡, Barbra A. Richardson5‡, Cynthia Grossman6, Sherri Johnson7‡,
Kailazarid Gomez7‡, Stephanie Horn7‡, Ratiya Pamela Kunjara Na Ayudhya8‡,
Karen Patterson9‡, Cindy Jacobson8‡, Linda-Gail Bekker10, Suwat Chariyalertsak11,
Anupong Chitwarakorn12, Pedro Gonzales13, Timothy H. Holtz14, Albert Liu15, Kenneth
H. Mayer16, Carmen Zorrilla17, Javier Lama13‡, Ian McGowan18, Ross D. Cranston18‡
1 HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia
University, New York, NY, United States of America, 2 Center for AIDS Prevention Studies, Department of
Medicine, University of California San Francisco, San Francisco, CA, United States of America, 3 Department
of Medicine, Johns Hopkins University, Baltimore, MD, United States of America, 4 Division of AIDS, National
Institute of Allergy and Infectious Diseases, Rockville, MD, United States of America, 5 Department of
Biostatistics, University of Washington, Seattle, WA, United States of America, 6 National Institute of Mental
Health, Bethesda, MD, United States of America, 7 FHI 360, Durham, NC, United States of America,
8 Magee-Womens Research Institute, Pittsburgh, PA, United States of America, 9 Statistical Center for HIV/
AIDS Research and Prevention, Seattle, WA, United States of America, 10 Desmond Tutu HIV Centre,
University of Cape Town, Cape Town, South Africa, 11 Research Institute for Health Sciences, Chiang Mai
University, Chiang Mai, Thailand, 12 Thailand Ministry of Public Health, Nonthaburi, Thailand, 13 Asociacio´n
Civil Impacta Salud y Educacio´n, Lima, Peru, 14 Thailand Ministry of Public Health—Centers for Disease
Control Collaboration, Bangkok, Thailand, 15 San Francisco Department of Public Health, San Francisco, CA,
United States of America, 16 The Fenway Institute, Boston, MA, United States of America, 17 Department of
Medicine, University of Puerto Rico, San Juan, PR, United States of America, 18 School of Medicine,
University of Pittsburgh, Pittsburgh, PA, United States of America
☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* ac72@cumc.columbia.edu
Abstract
Trials to assess microbicide safety require strict adherence to prescribed regimens. If adher-
ence is suboptimal, safety cannot be adequately assessed. MTN-017 was a phase 2, ran-
domized sequence, open-label, expanded safety and acceptability crossover study
comparing 1) daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), 2) daily use
of reduced-glycerin 1% tenofovir (RG-TFV) gel applied rectally, and 3) RG-TFV gel applied
before and after receptive anal intercourse (RAI)—if participants had no RAI in a week, they
were asked to use two doses of gel within 24 hours. Product use was assessed by mixed
methods including unused product return count, text messaging reports, and qualitative
plasma TFV pharmacokinetic (PK) results. Convergence interviews engaged participants in
determining the most accurate number of doses used based on product count and text
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messaging reports. Client-centered adherence counseling was also used. Participants (N =
187) were men who have sex with men and transgender women enrolled in the United
States (42%), Thailand (29%), Peru (19%) and South Africa (10%). Mean age was 31.4
years (range 18–64 years). Based on convergence interviews, over an 8-week period, 94%
of participants had80% adherence to daily tablet, 41% having perfect adherence; 83%
had80% adherence to daily gel, 29% having perfect adherence; and 93% had80%
adherence to twice-weekly use during the RAI-associated gel regimen, 75% having perfect
adherence and 77% having80% adherence to gel use before and after RAI. Only 4.4% of
all daily product PK results were undetectable and unexpected (TFV concentrations <0.31
ng/mL) given self-reported product use near sampling date. The mixed methods adherence
measurement indicated high adherence to product use in all three regimens. Adherence to
RAI-associated rectal gel use was as high as adherence to daily oral PrEP. A rectal microbi-
cide gel, if efficacious, could be an alternative for individuals uninterested in daily oral PrEP.
Introduction
Trials designed to assess the safety and effectiveness of microbicides and other drugs require
that participants adhere strictly to prescribed product use regimens. If adherence is subopti-
mal, safety and effectiveness cannot be adequately assessed. When product use does not occur
under direct observation of the researchers, accurate measurement of adherence is frequently
a challenge.
In HIV prevention and treatment trials, direct and indirect methods have been used to
measure adherence [1]. Direct methods include biological assays of active drug, metabolite or
other markers in blood, urine, other bodily fluids or hair to confirm active drug intake. Indi-
rect methods include tablet count, pharmacy refill records, electronic drug monitoring (e.g.,
MEMS Cap), therapeutic impact (e.g., viral load or CD4 T cell count), clinician assessment,
medical chart review and self-reports (quantitative and qualitative).
Unfortunately, all these methods have limitations. Direct methods of adherence assessment,
such as pharmacokinetic (PK) testing each sample type collected—plasma, hair, peripheral
blood mononuclear cells (PBMC), and dried blood spot–present a trade-off in accuracy of
recent dose-taking against averaging dose-taking over long periods, all of which are insensitive
to some periods of non-adherence. For example, plasma tenofovir (TFV) and PBMC TFV-
diphosphate (TFV-DP) can provide quantitative estimates of doses but only within the previ-
ous week, whereas TFV and TFV-DP in hair and dried blood spot respectively provide quanti-
tative measures of adherence averaged over one to several months but lack precision for
adherence in the most recent weeks [2–4]. Indirect methods of assessment are even more vul-
nerable to inaccuracies as tablet or applicator count may be affected, for example, by partici-
pants’ forgetting to return the products to the clinic or “dumping” (disposing of products
without using them) [5]. Self-reports may be affected by recall bias (a systematic error caused
by differences in the accuracy or completeness of participant’s recollections), especially con-
cerning habitual behaviors such as daily pill taking [6]; social desirability (tendency of some
individuals to respond in a way they deem to be more socially acceptable than their "true"
answer) [7,8]; and misrepresentation.
Given that structured surveys with forced response categories or even semi-structured
items may not suffice to understand nuances in product use, qualitative research methods
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(e.g., in-depth interviews [IDIs]) have been employed to better capture participants’ experience
of product use. Yet, while qualitative methods serve exploratory purposes and bring the
researchers closer to the “voice” of the participants, the results may not be generalizable.
In sum, currently there is no gold standard for the measurement of adherence to product
use in HIV prevention trials. In response to this critical challenge, some researchers have
resorted to mixed methods and triangulation (use of two or more measures for a single phe-
nomenon) [4,8]. For example, Pool et al. (2010) used mixed methods and triangulation in a
Phase III study of the vaginal microbicide candidate PRO-2000 (MDP301) [9,10]. Data were
collected from a random subsample of 725 women using structured case report form (CRF)
interviews, coital diaries and IDIs conducted with the participants and their partners.
Returned used and unused gel applicators were counted and additional data were collected
through focus group discussions and ethnography. Although the authors were able to assess
the most likely level of adherence to product use among study participants, they still identified
several problems with the measurements used. CRFs–the main source of self-report data on
behavior and adherence in many studies–were the least accurate with regard to measuring sex-
ual behavior, product and condom use. Although coital diaries should have been filled in close
to the coital event, they could have been completed shortly before having to turn them in,
which could have made them susceptible to recall and social desirability biases. IDIs carried
out in many different countries required extensive training of personnel, translation of inter-
view guides to different languages, translation of actual interviews back to English, and pro-
cessing of copious amounts of data. Partners were difficult to recruit, and few came. When
discrepant results were reported, male partners deferred to their female partners’ reports
(“counting how often you had sex is a ‘woman thing’”). Therefore, the mixed methods
approach, although conceptually interesting and recommended by Pool and colleagues, still
poses challenges.
This article describes the adherence measurement methods used in MTN-017, their imple-
mentation, and the adherence levels to product use observed in the trial. A separate publication
will describe the client-centered approach to counseling that was used in MTN-017 to support
and encourage good adherence to product use.
Methods
Study design and regimens
MTN-017 was reviewed and approved by IRBs at all participating institutions, including the
Centers for Disease Control and Prevention, the Thai Ministry of Public Health, the Thai Food
and Drug Administration, the University of Cape Town Research Ethics Council, the South
African Medicines Control Council, the Chiang Mai University Research Institute for Health
Sciences, Chiang Mai University Research Ethics Council, Fenway Community Health, Asocia-
cio´n Civil Impacta Salud y Educacio´n, the Peruvian National Institutes of Health, the Peruvian
Food and Drug Administration, the University of Puerto Rico, the University of Pittsburgh, and
the University of San Francisco, Committee on Human Research, and the NY State Psychiatric
Institute IRB (Protocol #6704), which approved the protocol on December 21, 2012. All partici-
pants signed a written informed consent form. The authors confirm that all ongoing and related
trials for this drug/intervention are registered.
MTN-017 was a Phase 2, randomized sequence, open-label, expanded safety and acceptabil-
ity crossover study which enrolled participants between September 2013 and November 2014
and compared 1) daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF); 2) daily
use of reduced-glycerin 1% tenofovir (RG-TFV) gel applied rectally; and 3) RG-TFV gel
applied before and after receptive anal intercourse (RAI). To assess product use in this study,
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we decided to build on Pool et al.’s (2010) mixed methods and triangulation approach while
enriching it based on our own experience in prior studies of the Microbicide Trials Network
(MTN-004, 006, 007, 012) and one independent study (Project Gel, R01 HD059533, Carballo-
Die´guez and McGowan, PIs). In these previous studies, we used a variety of assessment meth-
ods that included an interactive voice response telephone reporting system [11], computer
assisted self-interviews (CASI) [12], remote phone and video IDIs [13], and count of returned
used and unused applicators [12]. In addition, in MTN-017 we used telephone short message
system (SMS) for adherence reporting as well as also used detectable TFV concentration (cut-
off of 0.31 ng/mL) as a qualitative adherence measure provided to the clinical study team
within two weeks from sample collection.
The study consisted of three periods with a one-week washout period in between them (Fig
1). Each period lasted eight weeks and included three visits (initiate, mid-, and end-period vis-
its). There was an initial screening visit prior to enrollment/period 1. Follow-up of all enrolled
participants was completed in May 2015.
Participants were randomly assigned in equal numbers to use the product regimens in one
out of six possible sequences (Table 1). During the daily regimens, participants were instructed
to take one tablet orally (daily oral regimen) or to insert one dose of gel rectally per day (daily
rectal regimen) at approximately the same time every day. Missed doses were to be taken as
soon as possible, unless the next dose was estimated to be due within six hours, in which case,
the missed dose was skipped. During the RAI rectal regimen, participants were given instruc-
tions to follow the “BAT 24” dosing schedule used in CAPRISA 004 [14], inserting one dose of
gel up to 12 hours before RAI, a second dose of gel as soon as possible after RAI but within 12
hours of intercourse, and no more than two doses in 24 hours. Those who did not have RAI in
a 7-day period were instructed to insert two doses before the period ended.
Fig 1. MTN-017 study design. Pd:Period.
https://doi.org/10.1371/journal.pone.0181607.g001
Table 1. Study regimens in MTN-017.
Sequence Period 1
(8 weeks)
Washout
(~1 week)
Period 2
(8 weeks)
Washout
(~1 week)
Period 3
(8 weeks)
1 Daily Oral Daily Rectal RAI Rectal
2 RAI Rectal Daily Oral Daily Rectal
3 Daily Rectal RAI Rectal Daily Oral
4 Daily Rectal Daily Oral RAI Rectal
5 Daily Oral RAI Rectal Daily Rectal
6 RAI Rectal Daily Rectal Daily Oral
FTC: emtricitabine, TDF: tenofovir disoproxil fumarate, TFV: tenofovir; RAI: receptive anal intercourse, RG: reduced glycerin, Daily Rectal: Daily TFV-RG
1% gel, Daily Oral: Daily FTC/TDF, RAI Rectal: RAI-associated TFV-RG 1% gel
https://doi.org/10.1371/journal.pone.0181607.t001
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Study sites and participants
The study took place at eight sites in four countries: Cape Town (South Africa); Bangkok and
Chiang Mai (Thailand); Lima (Peru); and San Francisco, Pittsburgh, and Boston (US main-
land) as well as San Juan, Puerto Rico (US territory). Participants, recruited from a variety of
venues including the Internet, primary health clinics and community-based organizations,
included male and transgender females aged 18 years or older, non-HIV infected, in general
good health, with a history of RAI at least once in the past three months. More details on par-
ticipant eligibility criteria appear in Cranston RD et al. [15]].
Adherence measurement and support
Mixed methods were used to estimate adherence to product use during the trial. This is sche-
matically presented in Fig 2.
Product return. Participants in daily regimens were given bottles with 30 tablets or bags
with 30 applicators at the initiate-period visit to use over a 4-week period and were resupplied
at the mid-period visit, which was scheduled to occur 28 days later (see Fig 1). They were
asked to bring their bottle with unused tablets and all unused applicators to each mid- and
end-period visit. Therefore, for daily regimens, given that participants were expected to use
one dose per day, the expected number of doses taken at each follow-up was 28, for a total of
56 per regimen, although it could vary based on the follow-up visit window (the target visit
window was between 26 and 30 days). Only those participants who returned for their follow
up visit after 30 days would have no product left. Those in the RAI rectal regimen were
expected to use at least two doses per week, so the expected minimum number of doses taken
at each follow-up was 8, for a total of 16 per regimen, although it could vary based on fre-
quency of sexual activity. Site staff counted the number of unused products returned and
entered the data into the Product Dispensation and Return CRF. When participants forgot to
bring unused products back to the clinic, they were asked to estimate the number of unused
tablets or applicators not returned, and this was entered in a separate field of the CRF. Both
returned and unreturned unused doses were summed. That number was subtracted from the
Fig 2. Adherence measurement and counseling in MTN-017. SMS: Short message service, PK:
pharmacokinetic results, CASI: Computer Assisted Self-Interview.
https://doi.org/10.1371/journal.pone.0181607.g002
High adherence to rectal microbicide gel and oral PrEP in MTN-017
PLOS ONE | https://doi.org/10.1371/journal.pone.0181607 July 27, 2017 5 / 17
number of doses dispensed, and the result was also entered in the CRF as the estimated num-
ber of applicators used or tablets taken between visits based on product return.
SMS or text message reports. During all three periods, participants received daily text
messages at a time of their choice asking them how many times they had used the product
since their last report. Although we initially considered inquiring through SMS whether RAI
had occurred and if product use preceded and followed it, we decided against including these
questions to avoid significantly lengthening the daily SMS sessions. Participants received a
modest monetary compensation for each completed SMS session, plus a bonus if six out of
seven sessions per week were completed. Before each scheduled participant visit to the study
site, Columbia University staff prepared individual calendars for each participant depicting the
SMS reports received (or missing) for each day during the prior four weeks. Calendars were
uploaded to a secure data-sharing site for study staff use during the data convergence inter-
views, described below. Methods and challenges to implementing the SMS-based reminder
and survey system are further detailed in a separate publication [16].
Data convergence interview and adherence support. When participants returned to the
clinics at each visit they met with an adherence counselor who had been thoroughly trained on
client-centered interviewing techniques. The adherence counselor and participant reviewed
together the participant’s adherence to product use. The counselor showed the participant a data
convergence CRF documenting product return count and SMS report count for the previous
four weeks. Using a client-centered approach and following a written script, the counselor first
explained to the participants that discrepancies between different measures could be expected,
and subsequently engaged the participant’s collaboration to estimate together the most accurate
number of times the product had been used (“Which of these numbers–SMS and returned product
count—do you think best represents the actual number of times you used the product. Why?”) After
discussion with the participant, the counselor entered this number into the CRF along with an
explanation of any discrepancy between product return and SMS reports and how the most
accurate number was determined in such cases. Cognizant of the objections raised to the use of
the term “triangulation” in social research given its connotations of precision [10], we refer to
this process as data convergence. These initial questions were followed by client-centered adher-
ence support to reinforce attained adherence and encourage improvement when possible.
PK data interviews. At each mid- and end-period visit, plasma samples were collected for
PK testing to evaluate detection of study drug using the lower limit of quantitation of the assay
(0.31 ng/mL), regardless of study arm [17]. (Note: Detectable is not equivalent to protective oral
drug concentration [18]). Samples were analyzed at a single facility in Baltimore, US. Test
results were sent to study sites by the MTN laboratory center within two weeks of sample
receipt. At the first end-period visit and in subsequent mid- and end-period visits of the daily
regimens, adherence counselors conducted an interview that followed the same script as the
data convergence interview but also incorporated a discussion with the participant of whether
the PK tests detected or did not detect presence of TFV in their plasma. (“Last time, you
reported using the product XX times. Now, the blood work does/does not show any product in
your system. Why do you think that might be?). The PK result and participant’s explanation of
the observed results were documented on a PK data convergence CRF. No PK data interviews
were conducted during the RAI rectal regimen given the unpredictability of timing of product
use in relation to the time of plasma sampling.
Determination of final converged rates. Two or three Columbia University behavioral
team members independently reviewed the product return CRFs, SMS calendars, and data
convergence and PK data convergence CRFs. They determined the most likely adherence
score for each participant case by case, and discussed results with each other until reaching
consensus. In some cases, adherence determination was straightforward (e.g., product return
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count and SMS reports coincided, or discrepancies could be explained due to international
time differences between the study sites and Columbia University where the SMS calendars
were prepared). In other cases, especially when discrepancies were wider, attention was paid to
the participants’ explanations and the comments entered by the site adherence counselor, as
well as any external circumstances (e.g., problems scheduling interviews exactly at 4-week
intervals) that could account for the discrepancies. In no case was an undetectable PK result
used to modify an adherence score because there would have been no way to determine a new
score beyond what had emerged in the data convergence and PK interviews. However, unex-
pected negative PK results were carefully recorded, tallied, and discussed during the monthly
calls with the Adherence Working Group (discussed below).
Computer Assisted Self-Interview (CASI). At the end of each study period, participants
completed a CASI. It included several questions on frequency of RAI, product use on those
occasions (before, after, or both before-and-after), and product use during weeks when they
did not report RAI (for the RAI rectal regimen).
In-depth interviews (IDIs). Based on the final converged rates, a subset of participants
from each country/regimen, half with excellent adherence and half with poor adherence dur-
ing the first study period (regardless of regimen) were selected for IDIs. Excellent adherence
was operationalized as 100% product use during the daily regimens (oral and rectal) or at least
10 occasions of product use during the RAI rectal regimen. Poor adherence was initially opera-
tionalized as less than 60% product use during the daily regimens; however, when adherence
monitoring showed that very few participants fell under the 60% product use cutoff, the poor
adherence criterion was revised to include participants under 80% product use. The script for
the IDIs included questions on the experience using the product during the prior eight weeks,
challenges encountered, and strategies used to remember to use the product.
On-going monitoring. Thorough and continuous monitoring of the adherence measure-
ment and counseling system was in effect throughout the study.
SMS monitoring. SMS reporting was methodically controlled daily from the study
research offices at Columbia University in New York, US. This involved ongoing data cleaning
to eliminate duplicate reports, monitor incomplete sessions, and identify any other anomalies
[16]. When participants did not report within 48 hours, the Columbia University staff con-
tacted the site staff to alert them of the situation so that the site staff could contact the partici-
pant to follow up on potential problems.
Convergence and counseling monitoring. All data convergence and PK interviews as well
as adherence support discussions were audio recorded. Native Spanish, Thai and Xhosa-speak-
ing researchers on the Columbia University behavioral team who were also fluent in English fol-
lowed a standardized fidelity monitoring system. They reviewed the first 10 sessions of each
counselor, followed by one of every five for the next 15 sessions, and one of every 10 thereafter.
Adherence Working Group monitoring. The study team instituted an Adherence Work-
ing Group composed of the protocol chair and co-chair, members of the Columbia University
behavioral team, members of FHI360 (an organization that forms part of the MTN Leadership
and Operations Center and is responsible for study implementation management and site train-
ing), members of SCHARP (the statistical and data management center), the MTN study phar-
macist, and NIH staff. The adherence working group met by conference call approximately
once a month. In preparation for the call, the Columbia University behavioral team collected
information on all cases of participants assigned to daily regimens who had undetectable PK
results at mid or end-period visits. This information included the participant’s adherence based
on product return count and on SMS reports and calendars, explanations for discrepancies
offered to the site adherence counselor during the data convergence and PK interviews as well
as relevant information collected during adherence support sessions. Undetectable PK results
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were categorized as 1,“expected,” (i.e., cases in which the participant had reported interruption
of product use seven days prior to PK sample drawing in the oral periods and one day prior to
sample drawing in the daily rectal periods) or 2, “unexpected” (e.g., cases in which the partici-
pant had reported using the product at least once in the seven days prior to sample drawing in
the daily oral period or the day prior to sample drawing for the rectal daily period). This data-
review allowed the adherence working group to stay informed of any adherence irregularities
that might have required intervention.
Data management and analysis
Evaluable participants were those who were enrolled and not replaced, or were the final enrolled
replacement participant for another participant who was replaced. The MTN-017 study replaced
any participants with no adherence data available in either the daily rectal regimen or the RAI
rectal regimen (i.e., the participant was not dispensed study product and/or did not report on
study product use at least once in the daily rectal regimen, the RAI rectal regimen, or both). This
included cases where the adherence data were missing due to loss-to-follow-up, participant
refusal to use study product, or site–initiated product holds or discontinuations. These replace-
ment criteria were implemented to ensure enough person-years’ worth of data on the study gel
regimens to meet FDA safety requirements in preparation for a Phase III study. In total, eight
participants were replaced.
Adherence was calculated as the percentage of prescribed doses taken orally or adminis-
tered rectally during the visit window for each period, based on the Final Converged Rates
entered by the behavioral Columbia University team. For the RAI rectal regimen, the adher-
ence measures used were a) the percentage of doses taken out of an expected 8 doses per
4-week period; b) based on retrospective CASI reports, an occasion of RAI was considered
"adherent" only if the gel was used both before and after RAI (in accordance with study instruc-
tions); we also assessed if the gel was used either before or after RAI.
Descriptive statistics were generated for all evaluable participants based on their demo-
graphic characteristics. We also reported adherence rates by returned product count, SMS
messages, data convergence interview, and final converged rate.
The primary adherence scores were based on the final converged rate. We defined participants
with high adherence as those with adherence rates 80%. We employed the Generalized Linear
Model (GLM) to compare the proportion of participants with high adherence by regimen. Gen-
eralized Estimating Equations (GEE) was used to account for within subject correlation due to
repeated measures [19]. The model included regimen and study period as independent variables
with logit link function and exchangeable working correlation. We compared daily rectal and
RAI rectal to daily oral regimen and reported the adjusted odds ratio (AOR) as well as its corre-
sponding p-value and 95% confidence interval (95% CI).
We calculated the proportion of participants with high adherence by regimen and sequence.
To understand whether having used the gel daily prior to using it with RAI could influence high
adherence in the RAI rectal regimen, we calculated the proportion of high adherence rates in
the sequences in which participants used the gel daily before using it with RAI (i.e., sequences 1,
3, 4 in Table 1) and compared them to the sequences in which they used gel with RAI before
using it daily (i.e., sequences 2, 5, 6). Fisher’s Exact Test was used for the comparison.
Results
Sample description
Participants (N = 187) were recruited from the United States (N = 79, 42%), Thailand (N = 54,
29%), Peru (N = 36, 19%), and South Africa (N = 18, 10%). As shown in Table 2, their mean
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age was 31.4 years (range 18–64), and on average they had completed 12.3 years of education
(SD 1.9). Twelve percent were transgender women (TGW) by self-report. Most identified as
gay or homosexual. The three respondents identifying as heterosexual were two TGW and a
man. Participants had a median of 2.0 RAI occasions (M = 4.4, SD = 5.7) in the eight weeks
prior to baseline.
Adherence to scheduled product use
Table 3 presents the adherence to product use in the different regimens of the trial: daily oral,
daily rectal, and RAI rectal (regardless of actual occurrence of RAI) regimens. The table shows
the adherence measurements obtained independently from product return (including doses
not taken returned to the clinic and, separately, doses reportedly not taken but not returned to
the clinic), SMS reports of doses taken, data convergence interview estimates of doses taken,
final scores of doses taken after Columbia University behavioral team review, and overall per-
centage of participants adhering to product use80% of prescribed doses.
Product return. Based on product return, the estimated mean number of tablets the par-
ticipants took during the daily oral regimen was 51.1 (SD 8.9). Four percent of participants
took all tablets before returning to the clinic and therefore returned none; 88% of participants
had tablets left and brought them all to the clinic, for a mean of 6.7 tablets returned; and 8% of
participants had tablets left but did not return them to the clinic, the mean number of tablets
not returned and not taken for this subgroup being 4.7 (Standard Deviation (SD) 6.1, range
1–24) and for the whole sample, 0.4 (SD 2.0).
The estimated mean number of gel doses the participants used during the daily rectal regi-
men was 48.0 (SD 11.7). Six percent of participants had used all applicators before returning to
the clinic and therefore returned none; 87% had applicators left and returned them all to the
Table 2. Sample characteristics of the evaluable participants in MTN-017 (N = 187).
Mean (SD) Range
Age 31.4 (9.3) 18–64
Education (years) 12.3 (1.9) 0–13
N* %*
Currently working full- or part-time 144 79%
Currently in school full- or part-time 52 28%
Country of residence
Peru 36 19%
South Africa 18 10%
Thailand 54 29%
United States (including Puerto Rico) 79 42%
Gender
Man 163 88%
Transgender Woman 23 12%
Sexual identity
Gay/homosexual 164 91%
Bisexual 13 7%
Straight/heterosexual 3 2%
Mean (SD) Range
Frequency of receptive anal intercourse (past 8 weeks) 4.4 (5.7) 0–40
*Ns may not sum to 187 due to missing data; percentages are of those with non-missing data.
https://doi.org/10.1371/journal.pone.0181607.t002
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clinic, for a mean of 9.5 unused applicators returned; and 7% of participants had some applica-
tors left but did not return them all to the clinic, the mean number of unused and unreturned
applicators for this subgroup being 5.2 (SD 6.9, range 1–24) and for the whole sample, 0.4 (SD
2.2).
The mean number of doses taken during the RAI rectal regimen, regardless of occurrence
of RAI, was 23.1 (SD 12.5). In this regimen, 2.7% of participants had used all applicators before
returning to the clinic and therefore returned none; 90.8% had applicators left and returned
them all to the clinic for a mean of 30.9 unused applicators returned; and 6.5% had some appli-
cators left but did not return them all to the clinic, the mean number of unused and unre-
turned applicators for this subgroup being 5.50 (SD 11.57, range 1–42) and for the whole
sample, 0.4 (SD 3.1).
SMS. Table 3 also shows the accumulated tally of product use per regimen as reported
through SMS from the date of first report of the period until the date of calendar preparation
for discussion with participant during the data convergence interview. Doses taken according
to SMS reports were 46.4 (SD 10.7) for daily oral, 43.8 (SD 12.8) for daily rectal, and 20.6 (SD
12.0) for RAI rectal. For all regimens, the average number of doses taken based on SMS reports
was lower than the numbers of doses taken estimated on the basis of product return. This dif-
ference was observed even after sites with poor SMS reporting had been excluded.
Data convergence interview. In the data convergence interview, participants leaned
towards considering the product return count more accurate than the SMS reports. Several
reasons were given for this choice: At times, the calendars did not include the participants’ lat-
est reports (for example, a calendar could have been prepared on a Friday in New York for dis-
cussion on a Monday morning in Thailand). Other times, participants had been unable to
report on a daily basis plus, at the time of resuming reports, forgotten to provide the cumula-
tive number of doses taken since their latest report, which was the question posed in the SMS to
allow participants to report for more than one day if they missed a report, mitigating the need
to impute missing data from missed SMS reports. However, there were also cases in which par-
ticipants considered the SMS report more accurate due to having used an applicator incor-
rectly (e.g., accidentally discharging it before insertion or dropping the applicator on the
floor).
Table 3. Adherence: Prescribed doses taken orally or administered rectally per regimen in MTN-017.
Regimen Prescribed dose Expected
number of
doses taken1
Product
return
(Means (SD))
SMS Data
convergence
interview
Final
scores
% of participants
with high
adherence2
Doses not taken Doses
taken
Doses
taken
Doses taken Doses
taken
returned not
returned
Daily oral
(FTC/TDF)
1 tablet daily 56 tablets 6.7 (8.4) 0.4 (2.0) 51.1
(8.9)
46.4
(10.7)
51.3 (9.1) 51.1
(8.9)
94
Daily rectal
(TFV-RG 1%
gel)
1 applicator daily 56 applicators 9.5 (9.6) 0.4 (2.2) 48.0
(11.7)
43.8
(12.8)
48.4 (11.7) 48.0
(11.7)
83
RAI rectal
(TFV-RG 1%
gel)
At least 2
applicators every
7 days
At least 16
applicators
30.9 (13.5) 0.4 (3.1) 22.9
(12.6)
20.6
(12.0)
22.9 (12.7) 22.9
(12.6)
93
1Dependent on timing of the appointments.
2Proportion of participants per regimen achieving80% adherence to product use as prescribed.
https://doi.org/10.1371/journal.pone.0181607.t003
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Final converged adherence rates. The conclusions reached by participants and adherence
counselors during the data convergence interview were reviewed by the Columbia University
behavioral team following the monitoring procedures described in the methods section. Only
slight adjustments were made to ensure that the final rate was not higher than 100% (e.g., if a
participant reported using the product 30 times in 29 days), when reported scores were
deemed impossible based on further review of product count, or when the team’s quality con-
trol check identified typographical errors in the number reported, based on the numbers dis-
cussed during the audiotaped interview.
PK data interviews. Fig 3 shows the PK results from the daily regimens. Of 744 PK tests
performed at mid or end-period visits, 668 (89.8%) showed detectable results and 76 (10.2%)
undetectable results. Among the 668 detectable results, all but 5 were expected given the partic-
ipants’ reports of using the products within seven days prior to plasma sampling in the daily
oral period or the day prior to plasma sampling in the daily rectal period. Of the five unex-
pected detectable results (all in the daily rectal period) with no product use the day prior to
plasma sampling, one participant reported being on prescribed oral pre-exposure prophylaxis
(PrEP) with FTC/TDF obtained independently from the study. Among the 76 undetectable
results (not shown in Fig 3: 11 in the daily oral regimen and 65 in the daily rectal regimen), 43
were expected (e.g., the participant had reported not taking the product either seven days prior
to sample collection in the daily oral regimen or the day before sample collection in the daily
rectal regimen) and 33 unexpected (undetectable results despite reports of product use in the
days prior to sample collection). Of the 33 unexpected undetectable PK results, six were in the
daily oral and 27 in the daily rectal regimens. In sum, only 38 of the 744 PK results (5.1%) were
unexpected and not aligned with the data convergence interview results, and only 33 of the
744 PK results (4.4%) were negative PK results that did not support data convergence inter-
view reports. Table 4 presents examples of these unexpected negative PK results and the com-
ments the participants made during the interviews. Only three participants, all in the daily gel
regimen (two of them in Lima and one in San Francisco) had undetectable PKs at both mid-
Fig 3. Daily regimens PK results in MTN-017. PK: Pharmacokinetic.
https://doi.org/10.1371/journal.pone.0181607.g003
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and end-period visits. Given the types of explanations provided by participants as well as the
limitations of PK results to detect drug holidays or precise adherence in the recent weeks, PK
results could not be used to modify adherence scores.
Analysis of final converged adherence rates. An analysis of the final converged rates
based on product return, SMS, and DCIs shows that some participants had perfect adherence
to their regimens, including 41% in the daily oral regimen, 29% in the daily rectal regimen,
and 75% in the RAI rectal regimen (this last figure refers to having used the product at least
twice a week, regardless of intercourse). As shown in Table 3, 94% of participants in the daily
oral regimen took the tablet 80% of the prescribed occasions, and 83% in the daily rectal and
93% in the RAI rectal regimens used the gel 80% of prescribed occasions. In sum, high
adherence to product use was observed in all regimens. Yet, it was less likely during the daily
rectal regimen (Adjusted Odds Ratio (AOR) = 0.35, 95% CI = 0.19, 0.63, p<0.001) than during
the daily oral regimen. Adherence to gel use at least twice weekly during the RAI rectal regi-
men was similar to that for the daily oral regimen.
Table 5 shows the proportion of participants with high adherence to regimen use by
sequence. Comparing those who used the RAI rectal regimen after daily rectal (sequences 1, 3,
or 4) to those who used the RAI rectal regimen before daily rectal (sequences 2, 5, or 6) on the
proportion reporting high adherence, we found no significant differences (Fisher’s exact tests:
85% vs. 81%, p = 0.56 for daily rectal adherence; 93% vs. 93%, p = 0.99 for RAI rectal regimen
adherence).
Table 4. Examples of unexpected undetectable PK results in MTN-017.
Regimen Visit # Days between
visits
Doses
taken
Notes
Daily
rectal
3 28 25 SMS Report indicated product was used once per day until the weekend before the visit. Then no
product use on 10/18, 10/19, and 10/20 and then product use once per day on 10/21 and 10/22. His
visit was on 10/23. When participant was asked why he thought the test result was negative, he stated
that after using the product he would often go to the bathroom within 5–15 minutes of inserting it.
When this occurred he would notice gel in his stool.
Daily
rectal
6 28 28 SMS report indicates daily product use. During PK interview, participant stated that perhaps his PK
was not detectable because he was taking medicine for gastritis. He could not think of any other
reason why the result would be negative, and reassured the counselor that he had been taking the
product.
Daily oral 4 19 19 In the week prior to Visit 4, participant reported using product 7 times, but reported using it 1 time the
day before the visit, 3 times 2 days before the visit, and 0 times 3 days before the visit. In PK
convergence interview, participant doesn’t understand why his result is negative. Reviews calendar
carefully with counselor. Says that he took tablet regularly although was not always able to take it at
the same time each day. He wonders whether it might have been due to taking the tablet without food.
https://doi.org/10.1371/journal.pone.0181607.t004
Table 5. Proportion of participants with high adherence to product use by sequence in MTN-017.
Daily Oral Daily Rectal RAI Rectal
Sequence 1: ODR* 100% 87% 93%
Sequence 2: ROD* 90% 79% 90%
Sequence 3: DRO* 90% 87% 97%
Sequence 4: DOR* 90% 81% 90%
Sequence 5: ORD* 97% 78% 97%
Sequence 6: RDO* 94% 87% 90%
*O: daily FTC/TDF tablet; D: daily TFV-RG 1% gel; R: RAI TFV-RG 1% gel
Comparison of RAI after daily rectal (sequences 1, 3 or 4) to RAI before daily rectal (sequences 2, 5, or 6) on
daily rectal or RAI rectal was not statistically significant.
https://doi.org/10.1371/journal.pone.0181607.t005
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Adherence to product use before and after RAI
Regarding self-reported (CASI) adherence during the RAI rectal regimen, of the 187 evaluable
participants, six were missing data for this section of the assessment. The remaining 181 partici-
pants reported a median of 4.0 RAI occasions (M = 7.1; SD = 10.1) during the RAI rectal regi-
men with a median of 2.0 partners (M = 4.5; SD = 7.2). In addition, 23 (12.7%) reported no RAI
in the previous eight weeks and 128 (70.7%) reported at least one period of seven days when they
did not have intercourse. Of the 152 participants who answered the questions about gel use with
RAI, 18 (11.8%) had RAI occasions when they did not use any gel. Most common reasons for
not using the gel included forgetting, not having it on hand, and a change in the regular routine.
Adherence to product use before and after RAI, as prescribed by study design, was high,
with 77% of participants reporting80% adherence. Average adherence for using the gel both
before and after RAI was 85.1 (SD: 28.6; 95% CI: 80.5–89.7). Mean adherence for using the gel
before penetration was 90.5 (SD: 22.6; 95% CI: 86.9–94.2) and 89.5 (SD: 24.3; 95% CI: 85.6–
93.4) for using the gel after penetration. Average adherence for using the gel either before or
after RAI was 95.0 (SD: 17.5; 95% CI: 92.2–97.8).
Discussion
High levels of adherence to daily use of oral FTC/TDF, to RG-TFV applied daily, and to
RG-TFV applied at least twice per week or before-and-after RAI were achieved in MTN-017.
In all regimens, at least 83% of participants used the products on 80% of the prescribed occa-
sions according to our convergence adherence assessment. Our findings on oral FTC/TDF
adherence among MSM and TGW are similar to self-report data from the iPrex study, in
which at 8 weeks mean adherence to daily oral FTC/TDF was 93% [20]; however, further anal-
ysis found that only 51% of those reporting perfect adherence had drug detected [21], while in
this study real-time drug detection enabled us to converge adherence data throughout the
study. Our findings on RAI-associated rectal gel use are also similar to those from a previous
study on placebo gel use with RAI over a 3-month period, in which participants reported
using the gel before RAI on over 80% of occasions [12]. No long-term daily rectal gel studies
have been published to compare adherence scores.
The fact that adherence to oral FTC/TDF was high was not surprising given that daily [20]
and even intermittent [22] adherence to oral PrEP have shown effectiveness to prevent HIV
transmission, and participants in MTN-017 were aware of the effectiveness of daily oral FTC/
TDF. This was not the case for a rectal gel, whose potential effectiveness as a microbicide to
prevent HIV transmission is still unproven. From this perspective, the high adherence to gel
use both in the daily rectal and the RAI rectal regimens was remarkable, showing the strong
commitment of the participants to follow trial requirements.
The regimen that showed the lowest adherence rate was daily rectal gel. Although this regi-
men was selected in order to demonstrate the safety of the gel applied rectally, daily rectal gel
application was shown in our study to not be a practical way of delivering prevention of HIV
transmission during RAI. Self-administering a rectal gel daily may be cumbersome and less
comfortable than taking a daily tablet, especially for individuals who do not have RAI fre-
quently or regularly, as was the case with many of our participants. By contrast, self-adminis-
tering a gel around the time of RAI could be seen as a practical pre-coital, and even post-coital
protective measure, especially for individuals who have infrequent RAI. Interestingly, if the
rectal gel could prevent HIV transmission whether applied before or after RAI, 95% of the RAI
occasions that participants in our sample had would have been protected. Further research is
needed to identify the reasons that prevented 11.8% of participants from using the gel during
RAI occasions.
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From a measurement perspective, it is not possible to have 100% certitude on adherence to
product use during the trial, given that dose taking was not directly observed. Following Pool
et al. [10], we assume that the converged adherence estimates are the most accurate and plausi-
ble on pragmatic grounds, and potential corrections of the converged adherence estimates
based on the unexpected undetectable PK results would have had a negligible impact on the
final scores. However, we cannot rule out the possibility of deceit in which a participant could
have purposely reported product intake with SMS, used only one dose prior to returning to
the clinic (which would have resulted in a detectable PK reading) and dumped all the remain-
ing doses (so that product return count would have led us to assume high product use). Yet,
the open and collaborative interactions between participants and adherence counselors, which
were audio-recorded and monitored, lead us to believe that cases of deceit were nonexistent or
very scarce.
This was the first time in a rectal microbicide study that near-real time plasma PK test results
were provided to the study team and participant to assist with adherence assessment and
counseling. Being able to accomplish this with sites in four different continents and a central
laboratory processing specimens in the US was a major accomplishment. Furthermore, obtain-
ing almost 90% detectable and expected PK results in the daily regimens was a significant suc-
cess for this trial. The fact that 82% of unexpected undetectable results in the daily regimens
were observed in the rectal gel regimen may be explained by well-established differences in
plasma TFV concentrations that are far higher after oral than rectal dosing [23]. It should also
be considered whether behavioral issues (e.g., erroneous administration, urgency to evacuate
immediately post gel administration) or physiological ones (e.g., poor absorption) contribute to
such results.
The adherence measurement and support systems employed in this trial of less than 200
participants were specifically designed to optimize product use as prescribed to allow the eval-
uation of product safety. A trial with larger number of participants and different aims (e.g.,
evaluation of product effectiveness for HIV prevention) would require a different adherence
measurement and support design. For example, it would be ideal to simplify the tools used and
make measurement less labor intensive. Unfortunately, the design of MTN-017 does not allow
us to evaluate separately the relative accuracy of the different tools. At first glance, product
return count seems to offer values that are very close to the final adherence scores, and one
could be tempted to think that this measure alone suffices. However, participants in our study
were aware from the very beginning of the study that product return was just one of the mea-
sures of product use, and that they would discuss with an adherence counselor not just product
return but also SMS and PK reports.
Furthermore, the use of daily SMS messages may have worked as a reminder to use the
product. Also, the collaborative, client-centered approach used for adherence support may
have influenced the willingness of participants to adhere as closely as possible to the protocol
requirements as well as raised their consciousness on ways to maintain or improve product
use. To evaluate these interventions separately would require a different, specifically designed
study.
Caution is required to interpret our results. The high rates of product use achieved in the
trial do not indicate that comparable high rates would be observed in the “real world” or that
product use would reach drug concentrations sufficient to provide protection from HIV. Par-
ticipants in this trial may have been particularly motivated to fulfill trial requirements,
benefited from a highly supportive research environment, knew that they were carefully moni-
tored and agreed to it, and used the products only for 8-week periods. Microbicides used for
HIV prevention will require consistent and correct use for as long at the potential of HIV
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transmission exists, and this may be challenging. Nevertheless, MTN-017 shows the feasibility
of attaining high levels of adherence and the HIV prevention potential of these technologies.
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